Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 1997

View Archived Issues

TPO binding dynamics determined in vivo in mice

Newer valpromide analogues for treating epilepsy

Lp(a)-dependent actions of LMWH

CMV infection implicated in atherosclerosis

Low cholesterol levels contribute to increased mortality

Beneficial cardiovascular effects of garlic demonstrated in humans

Antiulcer drug shows bactericidal activity against H. pylori

Takeda's fumagillin analogue for microsporidial infections in AIDS patients

BMS compound excellent candidate for development in HBV

Mylan, Purepac and ESI Lederle report FDA generic approvals

U.S. patent covers obesity gene discovered by Millennium

U.S. patent covers protease inhibitors from Sparta and Univ. of Pennsylvania

Ergo Science's Ergoset enters phase II/III trials in obesity

Vical and Pasteur Merieux Connaught initiate phase I malaria trial

Knoll receives FDA approval to market Mavik for new indication

Allergan reports agents with retinoid-like activity

British Biotech: FY 1996/97 highlights

British Biotech describes orally active MMP/TNF inhibitors

UCLA isolates new antimicrobial agents

Novartis reports compounds with affinity for mGluR

5-HT1B antagonists from SmithKline Beecham

Novel NSAID for rheumatoid arthritis characterized by Fujisawa

Radiosensitizing and tumor-imaging effects of KADTF

More enediyne compounds from Sanwa Kagaku and Nagoya University

Gamma-pyrones for osteoporosis isolated from plant extract by Sumitomo Metal

R&D pipeline progress at Asta Medica

More on aspirin in cardiovascular medicine

Profile of a new formulation of eperisone hydrochloride

Novartis' R&D pipeline

Fujisawa reduces stake in Fujisawa Synthelabo

Mylan antianxiety/antipsychotic generic approved by FDA

FDA approves antibacterial generic from Mylan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...